Tate & Lyle Investments Limited agreed to acquire Quantum Hi-Tech (Guangdong) Biological Co., Ltd. from Chempartner Pharmatech Co., Ltd. (SZSE:300149) for CNY 1500 million on March 30, 2022. Chempartner Pharmatech's board of directors approved the transaction. As November 30, 2022, Quantum Hi-Tech (Guangdong) Biological reported the Total assets of CNY 268,686,400 and Net assets of CNY 172,838,300. The management team of Quantum will join Tate & Lyle at completion. The transaction is subject to approval by the shareholders of ChemPartner. The acquisition is expected to be accretive to revenue growth and EBITDA margin for Tate & Lyle in the first year of ownership. Andrew Boyd and Chuan Sun of Morrison & Foerster (UK) LLP acted as legal advisor to Tate and Lyle.

Tate & Lyle Investments Limited completed the acquisition of Quantum Hi-Tech (Guangdong) Biological Co., Ltd. from Chempartner Pharmatech Co., Ltd. (SZSE:300149) on June 9, 2022.